Overview

Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder

Status:
Completed
Trial end date:
2005-05-01
Target enrollment:
Participant gender:
Summary
This study evaluates changes in health related quality of life outcomes in patients using Oxytrol(r)
Phase:
Phase 4
Details
Lead Sponsor:
Watson Pharmaceuticals
Treatments:
Mandelic Acids
Oxybutynin